COMMUNIQUÉS West-GlobeNewswire

Catheter Precision Announces the Start of Enrollment for the LockeT Compare Study
21/08/2025
First patients have been enrolled Fort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced [...]
Immuneering Announces $25 Million Private Placement
21/08/2025
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a [...]
UroGen Pharma to Present at Upcoming Investor Conferences
21/08/2025
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Valitor Announces Upcoming Presentations at the Ophthalmology Futures Retina Forum and Euretina Conference, Including New Data for its Long-Acting Anti-VEGF Drug Candidate for Wet AMD, VLTR-559
21/08/2025
New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet age-related macular degeneration (AMD) to twice-yearly, will be presented [...]
Beta Bionics Announces Participation at Upcoming Investor Conferences
21/08/2025
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at [...]
Red Cross 2025 wildfires response is largest domestic operation in recent history
21/08/2025
Scale and complexity of wildfires operations surpass response to COVID-19 pandemic OTTAWA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross today announced that the 2025 wildfires response operation is the [...]
L’intervention de la Croix-Rouge en réponse aux feux de forêt de 2025 est la plus vaste des dernières années au pays
21/08/2025
L’ampleur et la complexité des opérations dépassent celles en réponse à la pandémie de COVID-19 OTTAWA, 21 août 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a annoncé aujourd’hui que les opérations en réponse aux [...]
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
21/08/2025
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease [...]
Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th
21/08/2025
WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 Annual Gateway [...]
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
21/08/2025
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a [...]
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
21/08/2025
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Pyxis Oncology to Participate in September Investor and Industry Conferences
21/08/2025
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. [...]
InflaRx Announces Participation in September Investor Conferences
21/08/2025
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.
21/08/2025
This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv ™ Rx device is pending Premarket [...]
Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia
21/08/2025
Parallel facilities strengthen continuous production and accelerate spider silk advancements ANN ARBOR, Mich., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs [...]
BioCryst to Present at Upcoming Investor Conference
21/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on [...]
Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
21/08/2025
SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]
Unleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused Elixir
21/08/2025
Mountain Shot Delivers an Elevated Whiskey Experience, Blending Smooth Chocolate Notes with a Refreshing Hint of Mint BRECKENRIDGE, Colo., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery , an award-winning [...]
I-Mab to Participate in September Investor Conferences
21/08/2025
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, [...]

Pages